|
|
Article: New York State Biotechnology Industry Opposed to State Restrictions on Medicaid Drugs; Medicaid Cost Containment Schemes Could Deny Patients Access to Biopharmaceuticals Discovered in New York, Negate Biotech Development Efforts.
- Article from:
- PR Newswire
- Article date:
- January 15, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ALBANY, N.Y. -- ALBANY, N.Y., Jan. 15 /PRNewswire/ -- The New York Biotechnology Association (NYBA) today announced that the Medicaid cost-cutting concepts being considered today by the state Assembly Committee on Health public hearing in Albany could impact patient health and severely damage efforts to develop New York state's rapidly growing biotechnology industry.
"NYBA and New York have been good partners in promoting biotech development for the state," said Ron Cohen, MD, President and CEO of Acorda Therapeutics, a New York based company that is a leader in developing therapies to repair spinal cord injuries. Dr. Cohen also serves as Chairman of the Board ...